Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability, Safety, and Tolerability of Eutropin Formulations in Healthy Volunteers
NCT04085224Phase 1Completed
- Sponsor
- LG Chem
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Eutropin in growth hormone deficiency (GHD), sponsored by LG Chem. Primary endpoint: Bioavailability at 2 years. Started Sep 2019; status: completed.
02
Drugs
Eutropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT04085224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085224.